How Healthy Adults Respond to the Nasal Flu Vaccine
Key facts
- Who runs it
- University of Alabama at Birmingham
- Where
- Birmingham, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Starts
- 1 Dec 2026
- Expected to end
- 30 Jun 2031
- Type of study
- Interventional
- Treatments tested
- FluMist (Live Attenuated Influenza Vaccine)
- Record updated
- 13 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Healthy adults aged 18 to 65 years
- Non-smokers (no smoking or vaping within the past 6 months)
- No chronic lung disease or significant chronic medical conditions
- No current or recent (within 1 month) upper or lower respiratory infection
- Able and willing to provide informed consent
- Have not received the current seasonal influenza vaccine
- Able to comply with study procedures and follow-up visits
Who cannot take part
- Receipt of influenza vaccine during the current season or within the past 2 weeks
- Receipt of another live vaccine within 4 weeks prior to enrollment or planned during study period
- Use of influenza antiviral medications (e.g., oseltamivir, zanamivir) within 48 hours prior to vaccination or planned use within 14 days after vaccination
- Immunocompromised individuals (including HIV/AIDS, immunosuppressive therapy, chemotherapy, or primary immunodeficiency)
- Chronic medical conditions including asthma, chronic lung, liver, kidney, neurologic, hematologic, metabolic, or significant cardiovascular disease (except isolated hypertension)
- History of chronic sinusitis or significant nasal allergies requiring frequent or daily treatment
- Acute moderate or severe illness at time of enrollment, with or without fever
- History of severe allergic reaction to influenza vaccine or any component of FluMist (including egg allergy if applicable)
- History of Guillain-Barré syndrome following influenza vaccination
- Any condition that, in the opinion of the investigator, would interfere with study participation or interpretation of results
- Age under 18 or over 65 years
- Pregnancy or breastfeeding
- Prisoners
- Non-English speaking individuals
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- University of Alabama at BirminghamBirmingham, United StatesContact: Shanna H Graves, AASNot yet recruiting
About the trial
What the trial wants to find out
This study is looking at how the immune system in the nose responds after receiving the FluMist nasal flu vaccine in healthy adults. FluMist is an FDA-approved influenza vaccine that is given as a nasal spray.
Read full original descriptionShow less
Healthy volunteers aged 18 to 65 who do not have chronic medical conditions, do not smoke, and have not recently received a flu vaccine will be enrolled. Participants will have three study visits over approximately one week. At the first visit, participants will be screened, give informed consent, and receive the FluMist vaccine. Nasal swabs and a gentle saline nasal wash will be collected before vaccination and again at two and four days after vaccination.
The samples collected will be used to study changes in immune cells, proteins, and viral activity in the nose using laboratory techniques such as gene expression and protein analysis. This information may help researchers better understand how flu vaccines work at the site where infection begins and may support the development of improved vaccines in the future.
There is no direct medical benefit expected for participants. Participation is voluntary, and all study procedures will be performed by trained clinical staff.
The group in the trial
- Healthy Adults Receiving Intranasal FluMist VaccinationTreatment being tested
Participants in this single-arm study will receive the FDA-approved live attenuated influenza vaccine (FluMist) administered intranasally according to standard dosing guidelines. All participants will undergo nasal sampling procedures, including nasal swabs and nasal wash, at baseline prior to vaccination and at approximately 2 and 4 days following vaccination. Samples will be collected to evaluate temporal changes in mucosal immune and epithelial responses using molecular and proteomic analyses. No placebo or comparator intervention is used.
Treatment: FluMist (Live Attenuated Influenza Vaccine)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Characterizing Local Mucosal Responses to Live Attenuated Influenza Vaccine in Healthy Adults
- Criteria questions
- Built from NCT07726862, who can take part
- Record updated
- 13 October 2026